Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1/PD-L1 inhibitors plus anlotinib as second-line therapy after chemo-immunotherapy failure in advanced NSCLC
ChiCTR2000038841Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate and Safety. Started Oct 2020; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000038841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038841.